Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review
Advanced epithelial ovarian cancer is one of the hardest human malignancies to treat. Standard treatment involves cytoreductive surgery and platinum-based chemotherapy, however, median progression-free survival for patients diagnosed with advanced stage disease (FIGO stages III and IV) is approximat...
Saved in:
| Published in | Biochimica et biophysica acta. General subjects Vol. 1863; no. 2; pp. 371 - 378 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.02.2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0304-4165 1872-8006 1872-8006 |
| DOI | 10.1016/j.bbagen.2018.11.005 |
Cover
| Abstract | Advanced epithelial ovarian cancer is one of the hardest human malignancies to treat. Standard treatment involves cytoreductive surgery and platinum-based chemotherapy, however, median progression-free survival for patients diagnosed with advanced stage disease (FIGO stages III and IV) is approximately 18 months. There has been little improvement in overall survival over the past decade and less than half of women with advanced stage disease will be living 5 years after diagnosis. A majority of patients initially have a favourable response to platinum-based chemotherapy, but most will eventually relapse and their disease will become platinum resistant.
Here, we review our current understanding of mechanisms that promote recurrence and acquired resistance in epithelial ovarian cancer with particular focus on studies that describe differences observed between untreated primary tumors and recurrent tumors, post-first-line chemotherapy. Multiple molecular mechanisms contribute to recurrence in patients following initial treatment for advanced epithelial ovarian cancer including those involving the tumor microenvironment, tumor immune status, cancer stem cells, DNA repair/cell survival pathways and extracellular matrix.
Due to the adaptive nature of recurrent tumors, the major contributing and specific resistance pattern may largely depend on the nature of the primary tumor itself.
Future work that aims to elucidate the complex pattern of acquired resistance will be useful for predicting chemotherapy response/recurrence following primary diagnosis and to develop novel treatment strategies to improve the survival of patients with advanced epithelial ovarian cancer, especially in tumors not harbouring homologous DNA recombination repair deficiencies.
•Advanced epithelial ovarian cancer has high relapse.•The major drug resistant pattern may depend on the primary tumor itself.•Tumor recurrence mechanisms involve the microenvironment, immune status, cancer stem cells, DNA repair/cell survival pathways and extracellular matrix. |
|---|---|
| AbstractList | Advanced epithelial ovarian cancer is one of the hardest human malignancies to treat. Standard treatment involves cytoreductive surgery and platinum-based chemotherapy, however, median progression-free survival for patients diagnosed with advanced stage disease (FIGO stages III and IV) is approximately 18 months. There has been little improvement in overall survival over the past decade and less than half of women with advanced stage disease will be living 5 years after diagnosis. A majority of patients initially have a favourable response to platinum-based chemotherapy, but most will eventually relapse and their disease will become platinum resistant.
Here, we review our current understanding of mechanisms that promote recurrence and acquired resistance in epithelial ovarian cancer with particular focus on studies that describe differences observed between untreated primary tumors and recurrent tumors, post-first-line chemotherapy. Multiple molecular mechanisms contribute to recurrence in patients following initial treatment for advanced epithelial ovarian cancer including those involving the tumor microenvironment, tumor immune status, cancer stem cells, DNA repair/cell survival pathways and extracellular matrix.
Due to the adaptive nature of recurrent tumors, the major contributing and specific resistance pattern may largely depend on the nature of the primary tumor itself.
Future work that aims to elucidate the complex pattern of acquired resistance will be useful for predicting chemotherapy response/recurrence following primary diagnosis and to develop novel treatment strategies to improve the survival of patients with advanced epithelial ovarian cancer, especially in tumors not harbouring homologous DNA recombination repair deficiencies. Advanced epithelial ovarian cancer is one of the hardest human malignancies to treat. Standard treatment involves cytoreductive surgery and platinum-based chemotherapy, however, median progression-free survival for patients diagnosed with advanced stage disease (FIGO stages III and IV) is approximately 18 months. There has been little improvement in overall survival over the past decade and less than half of women with advanced stage disease will be living 5 years after diagnosis. A majority of patients initially have a favourable response to platinum-based chemotherapy, but most will eventually relapse and their disease will become platinum resistant.BACKGROUNDAdvanced epithelial ovarian cancer is one of the hardest human malignancies to treat. Standard treatment involves cytoreductive surgery and platinum-based chemotherapy, however, median progression-free survival for patients diagnosed with advanced stage disease (FIGO stages III and IV) is approximately 18 months. There has been little improvement in overall survival over the past decade and less than half of women with advanced stage disease will be living 5 years after diagnosis. A majority of patients initially have a favourable response to platinum-based chemotherapy, but most will eventually relapse and their disease will become platinum resistant.Here, we review our current understanding of mechanisms that promote recurrence and acquired resistance in epithelial ovarian cancer with particular focus on studies that describe differences observed between untreated primary tumors and recurrent tumors, post-first-line chemotherapy. Multiple molecular mechanisms contribute to recurrence in patients following initial treatment for advanced epithelial ovarian cancer including those involving the tumor microenvironment, tumor immune status, cancer stem cells, DNA repair/cell survival pathways and extracellular matrix.SCOPE OF REVIEWHere, we review our current understanding of mechanisms that promote recurrence and acquired resistance in epithelial ovarian cancer with particular focus on studies that describe differences observed between untreated primary tumors and recurrent tumors, post-first-line chemotherapy. Multiple molecular mechanisms contribute to recurrence in patients following initial treatment for advanced epithelial ovarian cancer including those involving the tumor microenvironment, tumor immune status, cancer stem cells, DNA repair/cell survival pathways and extracellular matrix.Due to the adaptive nature of recurrent tumors, the major contributing and specific resistance pattern may largely depend on the nature of the primary tumor itself.MAJOR CONCLUSIONSDue to the adaptive nature of recurrent tumors, the major contributing and specific resistance pattern may largely depend on the nature of the primary tumor itself.Future work that aims to elucidate the complex pattern of acquired resistance will be useful for predicting chemotherapy response/recurrence following primary diagnosis and to develop novel treatment strategies to improve the survival of patients with advanced epithelial ovarian cancer, especially in tumors not harbouring homologous DNA recombination repair deficiencies.GENERAL SIGNIFICANCEFuture work that aims to elucidate the complex pattern of acquired resistance will be useful for predicting chemotherapy response/recurrence following primary diagnosis and to develop novel treatment strategies to improve the survival of patients with advanced epithelial ovarian cancer, especially in tumors not harbouring homologous DNA recombination repair deficiencies. Advanced epithelial ovarian cancer is one of the hardest human malignancies to treat. Standard treatment involves cytoreductive surgery and platinum-based chemotherapy, however, median progression-free survival for patients diagnosed with advanced stage disease (FIGO stages III and IV) is approximately 18 months. There has been little improvement in overall survival over the past decade and less than half of women with advanced stage disease will be living 5 years after diagnosis. A majority of patients initially have a favourable response to platinum-based chemotherapy, but most will eventually relapse and their disease will become platinum resistant.Here, we review our current understanding of mechanisms that promote recurrence and acquired resistance in epithelial ovarian cancer with particular focus on studies that describe differences observed between untreated primary tumors and recurrent tumors, post-first-line chemotherapy. Multiple molecular mechanisms contribute to recurrence in patients following initial treatment for advanced epithelial ovarian cancer including those involving the tumor microenvironment, tumor immune status, cancer stem cells, DNA repair/cell survival pathways and extracellular matrix.Due to the adaptive nature of recurrent tumors, the major contributing and specific resistance pattern may largely depend on the nature of the primary tumor itself.Future work that aims to elucidate the complex pattern of acquired resistance will be useful for predicting chemotherapy response/recurrence following primary diagnosis and to develop novel treatment strategies to improve the survival of patients with advanced epithelial ovarian cancer, especially in tumors not harbouring homologous DNA recombination repair deficiencies. Advanced epithelial ovarian cancer is one of the hardest human malignancies to treat. Standard treatment involves cytoreductive surgery and platinum-based chemotherapy, however, median progression-free survival for patients diagnosed with advanced stage disease (FIGO stages III and IV) is approximately 18 months. There has been little improvement in overall survival over the past decade and less than half of women with advanced stage disease will be living 5 years after diagnosis. A majority of patients initially have a favourable response to platinum-based chemotherapy, but most will eventually relapse and their disease will become platinum resistant. Here, we review our current understanding of mechanisms that promote recurrence and acquired resistance in epithelial ovarian cancer with particular focus on studies that describe differences observed between untreated primary tumors and recurrent tumors, post-first-line chemotherapy. Multiple molecular mechanisms contribute to recurrence in patients following initial treatment for advanced epithelial ovarian cancer including those involving the tumor microenvironment, tumor immune status, cancer stem cells, DNA repair/cell survival pathways and extracellular matrix. Due to the adaptive nature of recurrent tumors, the major contributing and specific resistance pattern may largely depend on the nature of the primary tumor itself. Future work that aims to elucidate the complex pattern of acquired resistance will be useful for predicting chemotherapy response/recurrence following primary diagnosis and to develop novel treatment strategies to improve the survival of patients with advanced epithelial ovarian cancer, especially in tumors not harbouring homologous DNA recombination repair deficiencies. •Advanced epithelial ovarian cancer has high relapse.•The major drug resistant pattern may depend on the primary tumor itself.•Tumor recurrence mechanisms involve the microenvironment, immune status, cancer stem cells, DNA repair/cell survival pathways and extracellular matrix. |
| Author | Suryo Rahmanto, Yohan Padilla, Monica Amaya Singomat, Terence Kaur, Pritinder Yu, Yu Binju, Mudra Cohen, Paul A. |
| Author_xml | – sequence: 1 givenname: Mudra surname: Binju fullname: Binju, Mudra organization: School of Pharmacy and Biomedical Sciences, Curtin University, Western Australia, Australia – sequence: 2 givenname: Monica Amaya surname: Padilla fullname: Padilla, Monica Amaya organization: School of Pharmacy and Biomedical Sciences, Curtin University, Western Australia, Australia – sequence: 3 givenname: Terence surname: Singomat fullname: Singomat, Terence organization: School of Pharmacy and Biomedical Sciences, Curtin University, Western Australia, Australia – sequence: 4 givenname: Pritinder surname: Kaur fullname: Kaur, Pritinder organization: School of Pharmacy and Biomedical Sciences, Curtin University, Western Australia, Australia – sequence: 5 givenname: Yohan surname: Suryo Rahmanto fullname: Suryo Rahmanto, Yohan organization: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, United States – sequence: 6 givenname: Paul A. surname: Cohen fullname: Cohen, Paul A. organization: Division of Obstetrics and Gynaecology, Faculty of Health and Medicine, University of Western Australia, Crawley, Western Australia, Australia – sequence: 7 givenname: Yu surname: Yu fullname: Yu, Yu email: yu.yu@curtin.edu.au organization: School of Pharmacy and Biomedical Sciences, Curtin University, Western Australia, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30423357$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUtv1DAUhS1URKeFf4CQl2wS7vUjDxZIqAJaqYgNrC3HuZnxKHGmdtKq_x6Ppt2wALyxZH3nyDrfBTsLcyDG3iKUCFh92JddZ7cUSgHYlIglgH7BNtjUomgAqjO2AQmqUFjpc3aR0h7y0a1-xc7zu5BS1xs2fCe3s8GnKfE19BTHRx-23Lq71Ufq-WG0iw_rxCMlnxYbHHEf-M5vd3wbbU88UZzXxOd7G70N3B2RyAtu-eSDz7l7Tw-v2cvBjonePN2X7NfXLz-vrovbH99urj7fFk62eimUqxUIrPq6ItRS1A2C0thVA4CUoq2kAu1IgEXVk1PdIFohrNTgGkJCecnen3oPcb5bKS1m8snRONpA-ZdGCIFQiRb-A0Uplazqps3ouyd07SbqzSH6ycZH8zxjBj6eABfnlCINxvklDzeHJVo_GgRzdGb25uTMHJ0ZRJOF5LD6I_zc_4_Yp1OM8p5542iS85TH77M4t5h-9n8v-A04NbCe |
| CitedBy_id | crossref_primary_10_1002_advs_201903718 crossref_primary_10_1016_j_ygyno_2019_10_019 crossref_primary_10_1186_s12920_020_00773_2 crossref_primary_10_1021_acs_jmedchem_3c00949 crossref_primary_10_1016_j_biopha_2023_115152 crossref_primary_10_3390_cancers11111786 crossref_primary_10_1097_MD_0000000000020053 crossref_primary_10_1186_s13148_021_01105_6 crossref_primary_10_3390_biomedicines9010056 crossref_primary_10_3390_cancers13143467 crossref_primary_10_2147_IJN_S247114 crossref_primary_10_1038_s41467_022_32272_6 crossref_primary_10_1186_s13048_019_0563_8 crossref_primary_10_1038_s41419_021_03665_0 crossref_primary_10_3390_ijms23094875 crossref_primary_10_3390_molecules26072084 crossref_primary_10_1016_j_tranon_2024_101939 crossref_primary_10_1080_15384101_2020_1838791 crossref_primary_10_1016_j_fitote_2024_106187 crossref_primary_10_1186_s12885_021_08166_z crossref_primary_10_3892_etm_2019_7803 crossref_primary_10_1016_j_ijpharm_2020_119986 crossref_primary_10_1007_s00281_022_00979_9 crossref_primary_10_1016_j_semcancer_2020_12_024 crossref_primary_10_1186_s13048_021_00939_1 crossref_primary_10_1186_s13048_019_0593_2 crossref_primary_10_3389_fimmu_2023_1177403 crossref_primary_10_1016_j_bbagen_2019_129452 crossref_primary_10_1007_s11033_023_08760_3 crossref_primary_10_1186_s13048_024_01461_w crossref_primary_10_15835_nbha49212363 crossref_primary_10_1007_s12032_022_01833_6 crossref_primary_10_1021_acsami_2c15143 crossref_primary_10_2147_CMAR_S337873 crossref_primary_10_1016_j_ygyno_2019_10_011 crossref_primary_10_3390_toxins11040237 |
| Cites_doi | 10.1097/PAS.0b013e3181cf3d79 10.1200/JCO.2006.06.0913 10.1002/ijc.29210 10.1200/JCO.2000.18.6.1193 10.1038/nature14410 10.1586/era.11.187 10.1111/IGC.0b013e3181a1c7aa 10.1038/nrc4019 10.1016/j.cell.2016.04.009 10.1016/S0140-6736(17)32440-6 10.1016/j.ygyno.2013.12.001 10.3390/ijms14046624 10.1038/bjc.2012.307 10.1023/A:1008240421028 10.1371/journal.pone.0006412 10.3389/fonc.2013.00251 10.1073/pnas.0509182102 10.1002/cncr.11310 10.1016/j.ygyno.2006.09.006 10.2353/ajpath.2010.100105 10.1016/j.semcancer.2014.06.004 10.1158/1535-7163.MCT-10-0788 10.1038/nm.2492 10.1158/1078-0432.CCR-11-2188 10.1038/nrc1123 10.1002/cncr.30196 10.1158/1078-0432.CCR-05-1244 10.1038/s41388-018-0241-0 10.1245/s10434-009-0357-0 10.1016/j.ygyno.2017.05.023 10.7150/jca.8610 10.3389/fonc.2013.00256 10.1158/1078-0432.CCR-08-0196 10.1002/ijc.30248 10.1007/s00404-010-1462-9 10.1016/S0140-6736(03)13718-X 10.1016/j.humpath.2018.06.018 10.1111/ajco.12449 10.1038/onc.2011.384 10.1158/1078-0432.CCR-17-1159 10.1038/s41467-017-00962-1 10.1016/j.ejca.2012.04.001 10.1080/08820139.2016.1186689 10.1016/S1470-2045(16)30559-9 10.1016/j.humpath.2017.12.010 10.1200/JCO.2008.16.1703 10.1016/j.trecan.2016.12.005 10.1177/1758834014544121 10.1016/j.ccell.2015.05.009 10.1097/AOG.0000000000000854 10.1007/s00262-008-0583-5 10.1158/0008-5472.CAN-08-2741 10.1200/JCO.2010.34.2980 10.1038/nrc1457 10.1038/onc.2011.610 10.1200/JCO.2009.27.5719 10.1200/JCO.2015.63.1408 10.1200/JCO.2009.25.7519 10.1016/0090-8258(90)90174-J 10.1016/j.ygyno.2012.03.006 10.1002/ijc.28335 10.1158/0008-5472.CAN-08-0088 10.1016/S1470-2045(06)70939-1 10.1200/JCO.1991.9.3.389 10.1038/nm1093 10.1200/JCO.2001.19.14.3312 10.1200/JCO.1997.15.6.2183 10.1371/journal.pone.0011198 10.1371/journal.pcbi.1002975 10.1006/gyno.2001.6151 10.1016/j.ygyno.2007.08.075 10.1038/ncomms11150 10.1186/bcr417 10.1016/j.ejphar.2014.07.025 |
| ContentType | Journal Article |
| Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION NPM 7X8 7S9 L.6 |
| DOI | 10.1016/j.bbagen.2018.11.005 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Biology |
| EISSN | 1872-8006 |
| EndPage | 378 |
| ExternalDocumentID | 30423357 10_1016_j_bbagen_2018_11_005 S0304416518303532 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABEFU ABFNM ABGSF ABMAC ABUDA ABXDB ABYKQ ACDAQ ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CS3 DOVZS EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HLW HVGLF HZ~ IHE J1W KOM LX3 M41 MO0 N9A O-L O9- OAUVE OHT OZT P-8 P-9 PC. Q38 R2- ROL RPZ SBG SCC SDF SDG SDP SES SEW SPCBC SSU SSZ T5K UQL WH7 WUQ XJT XPP ~G- AAHBH AATTM AAXKI AAYWO AAYXX ABWVN ACLOT ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD AGCQF AGRNS BNPGV NPM SSH 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c395t-4c740216d76e15327810451b6f00332963405ce20a14dec4bf2922a350c8e1e13 |
| IEDL.DBID | .~1 |
| ISSN | 0304-4165 1872-8006 |
| IngestDate | Sun Sep 28 03:50:30 EDT 2025 Mon Sep 29 03:26:00 EDT 2025 Mon Jul 21 05:55:19 EDT 2025 Wed Oct 01 00:42:40 EDT 2025 Thu Apr 24 23:03:19 EDT 2025 Fri Feb 23 02:34:16 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | Copyright © 2018 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c395t-4c740216d76e15327810451b6f00332963405ce20a14dec4bf2922a350c8e1e13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 30423357 |
| PQID | 2133436789 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2221062901 proquest_miscellaneous_2133436789 pubmed_primary_30423357 crossref_citationtrail_10_1016_j_bbagen_2018_11_005 crossref_primary_10_1016_j_bbagen_2018_11_005 elsevier_sciencedirect_doi_10_1016_j_bbagen_2018_11_005 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2019 2019-02-00 2019-Feb 20190201 |
| PublicationDateYYYYMMDD | 2019-02-01 |
| PublicationDate_xml | – month: 02 year: 2019 text: February 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Biochimica et biophysica acta. General subjects |
| PublicationTitleAlternate | Biochim Biophys Acta Gen Subj |
| PublicationYear | 2019 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Gore, Fryatt, Wiltshaw, Dawson (bb0055) 1990; 36 Bowtell, Bohm, Ahmed, Aspuria, Bast, Beral, Berek, Birrer, Blagden, Bookman, Brenton, Chiappinelli, Martins, Coukos, Drapkin, Edmondson, Fotopoulou, Gabra, Galon, Gourley, Heong, Huntsman, Iwanicki, Karlan, Kaye, Lengyel, Levine, Lu, McNeish, Menon, Narod, Nelson, Nephew, Pharoah, Powell, Ramos, Romero, Scott, Sood, Stronach, Balkwill (bb0080) 2015; 15 Luvero, Milani, Ledermann (bb0310) 2014; 6 Nieman, Kenny, Penicka, Ladanyi, Buell-Gutbrod, Zillhardt, Romero, Carey, Mills, Hotamisligil, Yamada, Peter, Gwin, Lengyel (bb0105) 2011; 17 Gordon, Fleagle, Guthrie, Parkin, Gore, Lacave (bb0365) 2001; 19 Parmar, Ledermann, Colombo, du Bois, Delaloye, Kristensen, Wheeler, Swart, Qian, Torri, Floriani, Jayson, Lamont, Trope (bb0340) 2003; 361 Shah, Landen (bb0205) 2014; 132 Tomao, Papa, Strudel, Rossi, Lo Russo, Benedetti Panici, Ciabatta, Tomao (bb0210) 2014; 5 Alberts, Liu, Wilczynski, Clouser, Lopez, Michelin, Lanzotti, Markman (bb0330) 2008; 108 Kurman, Shih Ie (bb0175) 2010; 34 ten Bokkel Huinink, Gore, Carmichael, Gordon, Malfetano, Hudson, Broom, Scarabelli, Davidson, Spanczynski, Bolis, Malmstrom, Coleman, Fields, Heron (bb0355) 1997; 15 Ahmed, Stenvers (bb0075) 2013; 3 Au Yeung, Co, Tsuruga, Yeung, Kwan, Leung, Li, Lu, Kwan, Wong, Schmandt, Lu, Mok (bb0110) 2016; 7 Norquist, Wurz, Pennil, Garcia, Gross, Sakai, Karlan, Taniguchi, Swisher (bb0295) 2011; 29 Wright, Chen, Tergas, Patankar, Burke, Hou, Neugut, Ananth, Hershman (bb0015) 2015; 125 Konstantinopoulos, Spentzos, Karlan, Taniguchi, Fountzilas, Francoeur, Levine, Cannistra (bb0280) 2010; 28 Ojalvo, Thompson, Wang, Meeker, Shih, Fader, Cimino-Mathews, Emens (bb0130) 2018; 74 Zhang, Ota, Shridhar, Chien, Wu, Kuang (bb0250) 2013; 9 Goh, Mohan, Ladwa, Ananda, Cohen, Baron-Hay (bb0025) 2015; 11 Galluzzi, Senovilla, Vitale, Michels, Martins, Kepp, Castedo, Kroemer (bb0065) 2012; 31 Curiel, Coukos, Zou, Alvarez, Cheng, Mottram, Evdemon-Hogan, Conejo-Garcia, Zhang, Burow, Zhu, Wei, Kryczek, Daniel, Gordon, Myers, Lackner, Disis, Knutson, Chen, Zou (bb0135) 2004; 10 Kudo, Gavin, Das, Amable, Shevde, Reed (bb0235) 2012; 31 Tanguay, Ansari, Buckley, Fernando (bb0315) 2009; 19 Bryant, Kumar, Spannuth, Shah, Munkarah, Deppe, Alvarez, Morris (bb0320) 2011; 283 Lengyel (bb0095) 2010; 177 Reinartz, Schumann, Finkernagel, Wortmann, Jansen, Meissner, Krause, Schworer, Wagner, Muller-Brusselbach, Muller (bb0170) 2014; 134 Jamieson, Sykes, Eva, Bergzoll, Simcock (bb0045) 2017; 146 Coleman, Oza, Lorusso, Aghajanian, Oaknin, Dean, Colombo, Weberpals, Clamp, Scambia, Leary, Holloway, Gancedo, Fong, Goh, O'Malley, Armstrong, Garcia-Donas, Swisher, Floquet, Konecny, McNeish, Scott, Cameron, Maloney, Isaacson, Goble, Grace, Harding, Raponi, Sun, Lin, Giordano, Ledermann (bb0385) 2017; 390 Cass, Baldwin, Varkey, Moslehi, Narod, Karlan (bb0265) 2003; 97 Markman, Rothman, Hakes, Reichman, Hoskins, Rubin, Jones, Almadrones, Lewis (bb0050) 1991; 9 Labidi-Galy, Papp, Hallberg, Niknafs, Adleff, Noe, Bhattacharya, Novak, Jones, Phallen, Hruban, Hirsch, Lin, Schwartz, Maire, Tille, Bowden, Ayhan, Wood, Scharpf, Kurman, Wang, Shih, Karchin, Drapkin, Velculescu (bb0180) 2017; 8 Patch, Christie, Etemadmoghadam, Garsed, George, Fereday, Nones, Cowin, Alsop, Bailey, Kassahn, Newell, Quinn, Kazakoff, Quek, Wilhelm-Benartzi, Curry, Leong, Hamilton, Mileshkin, Au-Yeung, Kennedy, Hung, Chiew, Harnett, Friedlander, Quinn, Pyman, Cordner, P. O'Brien, Leditschke, Young, Strachan, Waring, Azar, Mitchell, Traficante, Hendley, Thorne, Shackleton, Miller, Arnau, Tothill, Holloway, Semple, Harliwong, Nourse, Nourbakhsh, Manning, Idrisoglu, Bruxner, Christ, Poudel, Holmes, Anderson, Leonard, Lonie, Hall, Wood, Taylor, Fink, Waddell, Drapkin, Stronach, Gabra, Brown, Jewell, Nagaraj, Markham, Wilson, Ellul, McNally, Doyle, Vedururu, Stewart, Lengyel, Pearson, deFazio, Grimmond, Bowtell (bb0115) 2015; 521 Yu, Gaillard, Phillip, Huang, Pinto, Tessarollo, Zhang, Pandey, Wirtz, Ayhan, Davidson, Wang, Shih Ie (bb0190) 2015; 28 Piccart, Green, Lacave, Reed, Vergote, Benedetti-Panici, Bonetti, Kristeller-Tome, Fernandez, Curran, Van Glabbeke, Lacombe, Pinel, Pecorelli (bb0360) 2000; 18 Tan, Rothermundt, Thomas, Bancroft, Eeles, Shanley, Ardern-Jones, Norman, Kaye, Gore (bb0270) 2008; 26 Rizzo, Hersey, Mellor, Dai, Santos-Silva, Liber, Luk, Titley, Carden, Box, Hudson, Kaye, Brown (bb0220) 2011; 10 Agarwal, Kaye (bb0070) 2003; 3 Turner, Tutt, Ashworth (bb0275) 2004; 4 Sato, Olson, Ahn, Bundy, Nishikawa, Qian, Jungbluth, Frosina, Gnjatic, Ambrosone, Kepner, Odunsi, Ritter, Lele, Chen, Ohtani, Old, Odunsi (bb0160) 2005; 102 Wagner, Marth, Largillier, Kaern, Brown, Heywood, Bonaventura, Vergote, Piccirillo, Fossati, Gebski, Lauraine (bb0350) 2012; 107 Tan, Agarwal, Kaye (bb0085) 2006; 7 Bozas, Bamias, Koutsoukou, Efstathiou, Gika, Papadimitriou, Dimopoulos (bb0370) 2007; 104 Pfisterer, Plante, Vergote, du Bois, Hirte, Lacave, Wagner, Stahle, Stuart, Kimmig, Olbricht, Le, Emerich, Kuhn, Bentley, Jackisch, Luck, Rochon, Zimmermann, Eisenhauer, Ago, Ncic, Eortc (bb0035) 2006; 24 S. Zhang, B. Cui, H. Lai, G. Liu, E.M. Ghia, G.F. Widhopf, II, Z. Zhang, C.C. Wu, L. Chen, R. Wu, R. Schwab, D.A. Carson, T.J. Kipps, Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy, Proc. Natl. Acad. Sci. U. S. A., 111 (2014) 17266–17271. Leffers, Gooden, de Jong, Hoogeboom, ten Hoor, Hollema, Boezen, van der Zee, Daemen, Nijman (bb0150) 2009; 58 Rakowski, Ahmad, Holloway (bb0345) 2012; 12 Swisher, Lin, Oza, Scott, Giordano, Sun, Konecny, Coleman, Tinker, O'Malley, Kristeleit, Ma, Bell-McGuinn, Brenton, Cragun, Oaknin, Ray-Coquard, Harrell, Mann, Kaufmann, Floquet, Leary, Harding, Goble, Maloney, Isaacson, Allen, Rolfe, Yelensky, Raponi, McNeish (bb0390) 2017; 18 Wolf, Wolf, Rumpold, Fiegl, Zeimet, Muller-Holzner, Deibl, Gastl, Gunsilius, Marth (bb0140) 2005; 11 Chkourko Gusky, Diedrich, MacDougald, Podgorski (bb0100) 2016; Vol. 17 Wang, Kryczek, Dostal, Lin, Tan, Zhao, Lu, Wei, Maj, Peng, He, Vatan, Szeliga, Kuick, Kotarski, Tarkowski, Dou, Rattan, Munkarah, Liu, Zou (bb0165) 2016; 165 Jinawath, Vasoontara, Jinawath, Fang, Zhao, Yap, Guo, Lee, Wang, Balgley, Davidson, Wang, Shih Ie (bb0185) 2010; 5 Bandera, Fay, Giovannucci, Leitzmann, Marklew, McTiernan, Mullee, Romieu, Thune, Uauy, Wiseman, World Cancer (bb0005) 2016; 139 Ferlay, Soerjomataram, Dikshit, Eser, Mathers, Rebelo, Parkin, Forman, Bray (bb0010) 2015; 136 Del Carmen, Supko, Horick, Rauh-Hain, Clark, Campos, Krasner, Atkinson, Birrer (bb0030) 2016; 122 Milne, Kobel, Kalloger, Barnes, Gao, Gilks, Watson, Nelson (bb0145) 2009; 4 Swisher, Sakai, Karlan, Wurz, Urban, Taniguchi (bb0300) 2008; 68 Foley, Rauh-Hain, del Carmen (bb0395) 2013; 27 Prat, D'Angelo, Espinosa (bb0020) 2018; 80 Yu, Suryo Rahmanto, Lee, Wu, Phillip, Huang, Vitolo, Gaillard, Martin, Wirtz, Shih, Wang (bb0195) 2018; 37 Harter, Hahmann, Lueck, Poelcher, Wimberger, Ortmann, Canzler, Richter, Wagner, Hasenburg, Burges, Loibl, Meier, Huober, Fink, Schroeder, Muenstedt, Schmalfeldt, Emons, du Bois (bb0305) 2009; 16 Liu, West (bb0255) 2002; 4 Poveda, Selle, Hilpert, Reuss, Savarese, Vergote, Witteveen, Bamias, Scotto, Mitchell, Pujade-Lauraine (bb0380) 2015; 33 Dasari, Tchounwou (bb0285) 2014; 740 Monk, Herzog, Kaye, Krasner, Vermorken, Muggia, Pujade-Lauraine, Park, Parekh, Poveda (bb0375) 2012; 48 Tothill, Tinker, George, Brown, Fox, Lade, Johnson, Trivett, Etemadmoghadam, Locandro, Traficante, Fereday, Hung, Chiew, Haviv, Australian Ovarian, Cancer Study, Gertig, DeFazio (bb0120) 2008; 14 Chien, Kuang, Landen, Shridhar (bb0245) 2013; 3 Kwon, Shin (bb0225) 2013; 14 Steg, Bevis, Katre, Ziebarth, Dobbin, Alvarez, Zhang, Conner, Landen (bb0230) 2012; 18 Eastman (bb0290) 1990; 2 Parmar, Ledermann, Colombo, du Bois, Delaloye, Kristensen, Wheeler, Swart, Qian, Torri, Floriani, Jayson, Lamont, Trope (bb0040) 2003; 361 Eisenhauer, Vermorken, van Glabbeke (bb0060) 1997; 8 Cojoc, Mabert, Muders, Dubrovska (bb0215) 2015; 31 Bolis, Scarfone, Giardina, Villa, Mangili, Melpignano, Presti, Tateo, Franchi, Parazzini (bb0325) 2001; 81 Pogge Von Strandmann, Reinartz, Wager, Muller (bb0090) 2017; 3 Singh, Loftus, Webb, Benencia (bb0155) 2016; 45 Kreuzinger, Geroldinger, Smeets, Braicu, Sehouli, Koller, Wolf, Darb-Esfahani, Joehrens, Vergote, Vanderstichele, Boeckx, Lambrechts, Gabra, Wisman, Trillsch, Heinze, Horvat, Polterauer, Berns, Theillet, Cacsire Castillo-Tong (bb0125) 2017; 23 Pujade-Lauraine, Wagner, Aavall-Lundqvist, Gebski, Heywood, Vasey, Volgger, Vergote, Pignata, Ferrero, Sehouli, Lortholary, Kristensen, Jackisch, Joly, Brown, Le Fur, du Bois (bb0335) 2010; 28 Dann, Deloia, Timms, Zorn, Potter, Flake, Lanchbury, Krivak (bb0260) 2012; 125 Charafe-Jauffret, Ginestier, Iovino, Wicinski, Cervera, Finetti, Hur, Diebel, Monville, Dutcher, Brown, Viens, Xerri, Bertucci, Stassi, Dontu, Birnbaum, Wicha (bb0200) 2009; 69 Parmar (10.1016/j.bbagen.2018.11.005_bb0340) 2003; 361 Leffers (10.1016/j.bbagen.2018.11.005_bb0150) 2009; 58 Steg (10.1016/j.bbagen.2018.11.005_bb0230) 2012; 18 Konstantinopoulos (10.1016/j.bbagen.2018.11.005_bb0280) 2010; 28 Chkourko Gusky (10.1016/j.bbagen.2018.11.005_bb0100) 2016; Vol. 17 Harter (10.1016/j.bbagen.2018.11.005_bb0305) 2009; 16 Pujade-Lauraine (10.1016/j.bbagen.2018.11.005_bb0335) 2010; 28 Norquist (10.1016/j.bbagen.2018.11.005_bb0295) 2011; 29 Prat (10.1016/j.bbagen.2018.11.005_bb0020) 2018; 80 Dasari (10.1016/j.bbagen.2018.11.005_bb0285) 2014; 740 Ahmed (10.1016/j.bbagen.2018.11.005_bb0075) 2013; 3 Wagner (10.1016/j.bbagen.2018.11.005_bb0350) 2012; 107 Alberts (10.1016/j.bbagen.2018.11.005_bb0330) 2008; 108 Tan (10.1016/j.bbagen.2018.11.005_bb0085) 2006; 7 Nieman (10.1016/j.bbagen.2018.11.005_bb0105) 2011; 17 Yu (10.1016/j.bbagen.2018.11.005_bb0190) 2015; 28 Del Carmen (10.1016/j.bbagen.2018.11.005_bb0030) 2016; 122 Gordon (10.1016/j.bbagen.2018.11.005_bb0365) 2001; 19 Dann (10.1016/j.bbagen.2018.11.005_bb0260) 2012; 125 Jinawath (10.1016/j.bbagen.2018.11.005_bb0185) 2010; 5 Shah (10.1016/j.bbagen.2018.11.005_bb0205) 2014; 132 Yu (10.1016/j.bbagen.2018.11.005_bb0195) 2018; 37 Swisher (10.1016/j.bbagen.2018.11.005_bb0300) 2008; 68 Ojalvo (10.1016/j.bbagen.2018.11.005_bb0130) 2018; 74 Curiel (10.1016/j.bbagen.2018.11.005_bb0135) 2004; 10 Bryant (10.1016/j.bbagen.2018.11.005_bb0320) 2011; 283 Goh (10.1016/j.bbagen.2018.11.005_bb0025) 2015; 11 Bozas (10.1016/j.bbagen.2018.11.005_bb0370) 2007; 104 Au Yeung (10.1016/j.bbagen.2018.11.005_bb0110) 2016; 7 Coleman (10.1016/j.bbagen.2018.11.005_bb0385) 2017; 390 Pfisterer (10.1016/j.bbagen.2018.11.005_bb0035) 2006; 24 10.1016/j.bbagen.2018.11.005_bb0240 Eastman (10.1016/j.bbagen.2018.11.005_bb0290) 1990; 2 Tanguay (10.1016/j.bbagen.2018.11.005_bb0315) 2009; 19 Gore (10.1016/j.bbagen.2018.11.005_bb0055) 1990; 36 Bowtell (10.1016/j.bbagen.2018.11.005_bb0080) 2015; 15 Patch (10.1016/j.bbagen.2018.11.005_bb0115) 2015; 521 Tothill (10.1016/j.bbagen.2018.11.005_bb0120) 2008; 14 Tomao (10.1016/j.bbagen.2018.11.005_bb0210) 2014; 5 Wang (10.1016/j.bbagen.2018.11.005_bb0165) 2016; 165 Zhang (10.1016/j.bbagen.2018.11.005_bb0250) 2013; 9 ten Bokkel Huinink (10.1016/j.bbagen.2018.11.005_bb0355) 1997; 15 Singh (10.1016/j.bbagen.2018.11.005_bb0155) 2016; 45 Parmar (10.1016/j.bbagen.2018.11.005_bb0040) 2003; 361 Labidi-Galy (10.1016/j.bbagen.2018.11.005_bb0180) 2017; 8 Reinartz (10.1016/j.bbagen.2018.11.005_bb0170) 2014; 134 Agarwal (10.1016/j.bbagen.2018.11.005_bb0070) 2003; 3 Galluzzi (10.1016/j.bbagen.2018.11.005_bb0065) 2012; 31 Rakowski (10.1016/j.bbagen.2018.11.005_bb0345) 2012; 12 Cass (10.1016/j.bbagen.2018.11.005_bb0265) 2003; 97 Poveda (10.1016/j.bbagen.2018.11.005_bb0380) 2015; 33 Lengyel (10.1016/j.bbagen.2018.11.005_bb0095) 2010; 177 Foley (10.1016/j.bbagen.2018.11.005_bb0395) 2013; 27 Bolis (10.1016/j.bbagen.2018.11.005_bb0325) 2001; 81 Luvero (10.1016/j.bbagen.2018.11.005_bb0310) 2014; 6 Eisenhauer (10.1016/j.bbagen.2018.11.005_bb0060) 1997; 8 Charafe-Jauffret (10.1016/j.bbagen.2018.11.005_bb0200) 2009; 69 Wolf (10.1016/j.bbagen.2018.11.005_bb0140) 2005; 11 Turner (10.1016/j.bbagen.2018.11.005_bb0275) 2004; 4 Piccart (10.1016/j.bbagen.2018.11.005_bb0360) 2000; 18 Wright (10.1016/j.bbagen.2018.11.005_bb0015) 2015; 125 Rizzo (10.1016/j.bbagen.2018.11.005_bb0220) 2011; 10 Sato (10.1016/j.bbagen.2018.11.005_bb0160) 2005; 102 Cojoc (10.1016/j.bbagen.2018.11.005_bb0215) 2015; 31 Tan (10.1016/j.bbagen.2018.11.005_bb0270) 2008; 26 Markman (10.1016/j.bbagen.2018.11.005_bb0050) 1991; 9 Ferlay (10.1016/j.bbagen.2018.11.005_bb0010) 2015; 136 Liu (10.1016/j.bbagen.2018.11.005_bb0255) 2002; 4 Jamieson (10.1016/j.bbagen.2018.11.005_bb0045) 2017; 146 Kudo (10.1016/j.bbagen.2018.11.005_bb0235) 2012; 31 Chien (10.1016/j.bbagen.2018.11.005_bb0245) 2013; 3 Swisher (10.1016/j.bbagen.2018.11.005_bb0390) 2017; 18 Bandera (10.1016/j.bbagen.2018.11.005_bb0005) 2016; 139 Kreuzinger (10.1016/j.bbagen.2018.11.005_bb0125) 2017; 23 Kwon (10.1016/j.bbagen.2018.11.005_bb0225) 2013; 14 Pogge Von Strandmann (10.1016/j.bbagen.2018.11.005_bb0090) 2017; 3 Milne (10.1016/j.bbagen.2018.11.005_bb0145) 2009; 4 Kurman (10.1016/j.bbagen.2018.11.005_bb0175) 2010; 34 Monk (10.1016/j.bbagen.2018.11.005_bb0375) 2012; 48 |
| References_xml | – volume: 136 start-page: E359 year: 2015 end-page: E386 ident: bb0010 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int. J. Cancer – volume: 19 start-page: 3312 year: 2001 end-page: 3322 ident: bb0365 article-title: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan publication-title: J. Clin. Oncol. – volume: 28 start-page: 3323 year: 2010 end-page: 3329 ident: bb0335 article-title: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse publication-title: J. Clin. Oncol. – volume: 36 start-page: 207 year: 1990 end-page: 211 ident: bb0055 article-title: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds publication-title: Gynecol. Oncol. – volume: 2 start-page: 275 year: 1990 end-page: 280 ident: bb0290 article-title: Activation of programmed cell death by anticancer agents: cisplatin as a model system publication-title: Cancer Cells – volume: 33 start-page: 3836 year: 2015 end-page: 3838 ident: bb0380 article-title: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA Trial publication-title: J. Clin. Oncol. – volume: 68 start-page: 2581 year: 2008 end-page: 2586 ident: bb0300 article-title: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance publication-title: Cancer Res. – volume: 3 start-page: 502 year: 2003 end-page: 516 ident: bb0070 article-title: Ovarian cancer: strategies for overcoming resistance to chemotherapy publication-title: Nat. Rev. Cancer – volume: 8 start-page: 1093 year: 2017 ident: bb0180 article-title: High grade serous ovarian carcinomas originate in the fallopian tube publication-title: Nat. Commun. – volume: 28 start-page: 82 year: 2015 end-page: 96 ident: bb0190 article-title: Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules publication-title: Cancer Cell – volume: 107 start-page: 588 year: 2012 end-page: 591 ident: bb0350 article-title: Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients publication-title: Br. J. Cancer – volume: 10 start-page: 942 year: 2004 end-page: 949 ident: bb0135 article-title: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival publication-title: Nat. Med. – volume: 69 start-page: 1302 year: 2009 end-page: 1313 ident: bb0200 article-title: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature publication-title: Cancer Res. – volume: 104 start-page: 580 year: 2007 end-page: 585 ident: bb0370 article-title: Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma publication-title: Gynecol. Oncol. – volume: 139 start-page: 2391 year: 2016 end-page: 2397 ident: bb0005 article-title: Research fund international continuous update project, the use and interpretation of anthropometric measures in cancer epidemiology: a perspective from the world cancer research fund international continuous update project publication-title: Int. J. Cancer – volume: 17 start-page: 1498 year: 2011 end-page: 1503 ident: bb0105 article-title: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth publication-title: Nat. Med. – volume: 15 start-page: 2183 year: 1997 end-page: 2193 ident: bb0355 article-title: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer publication-title: J. Clin. Oncol. – volume: 14 start-page: 6624 year: 2013 end-page: 6648 ident: bb0225 article-title: Regulation of ovarian cancer stem cells or tumor-initiating cells publication-title: Int. J. Mol. Sci. – volume: 26 start-page: 5530 year: 2008 end-page: 5536 ident: bb0270 article-title: "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations publication-title: J. Clin. Oncol. – volume: 102 start-page: 18538 year: 2005 end-page: 18543 ident: bb0160 article-title: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 34 start-page: 433 year: 2010 end-page: 443 ident: bb0175 article-title: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory publication-title: Am. J. Surg. Pathol. – volume: 11 start-page: 1 year: 2015 end-page: 16 ident: bb0025 article-title: Frontline treatment of epithelial ovarian cancer publication-title: Asia Pac. J. Clin. Oncol. – volume: 18 start-page: 1193 year: 2000 end-page: 1202 ident: bb0360 article-title: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group publication-title: J. Clin. Oncol. – volume: 146 start-page: 273 year: 2017 end-page: 278 ident: bb0045 article-title: Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence publication-title: Gynecol. Oncol. – volume: 9 start-page: 389 year: 1991 end-page: 393 ident: bb0050 article-title: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin publication-title: J. Clin. Oncol. – volume: 740 start-page: 364 year: 2014 end-page: 378 ident: bb0285 article-title: Cisplatin in cancer therapy: molecular mechanisms of action publication-title: Eur. J. Pharmacol. – volume: 5 start-page: 301 year: 2014 end-page: 310 ident: bb0210 article-title: Investigating molecular profiles of ovarian cancer: an update on cancer stem cells publication-title: J. Cancer – volume: 134 start-page: 32 year: 2014 end-page: 42 ident: bb0170 article-title: Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse publication-title: Int. J. Cancer – volume: 8 start-page: 963 year: 1997 end-page: 968 ident: bb0060 article-title: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments] publication-title: Ann. Oncol. – volume: 6 start-page: 229 year: 2014 end-page: 239 ident: bb0310 article-title: Treatment options in recurrent ovarian cancer: latest evidence and clinical potential publication-title: Ther. Adv. Med. Oncol. – volume: 7 start-page: 925 year: 2006 end-page: 934 ident: bb0085 article-title: Mechanisms of transcoelomic metastasis in ovarian cancer publication-title: Lancet Oncology – volume: 5 year: 2010 ident: bb0185 article-title: Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma publication-title: PLoS One – volume: 9 year: 2013 ident: bb0250 article-title: Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment publication-title: PLoS Comput. Biol. – volume: 48 start-page: 2361 year: 2012 end-page: 2368 ident: bb0375 article-title: Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis publication-title: Eur. J. Cancer – volume: 97 start-page: 2187 year: 2003 end-page: 2195 ident: bb0265 article-title: Improved survival in women with BRCA-associated ovarian carcinoma publication-title: Cancer – volume: 125 start-page: 1345 year: 2015 end-page: 1352 ident: bb0015 article-title: Trends in relative survival for ovarian cancer from 1975 to 2011 publication-title: Obstet. Gynecol. – volume: 28 start-page: 3555 year: 2010 end-page: 3561 ident: bb0280 article-title: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer publication-title: J. Clin. Oncol. – volume: 58 start-page: 449 year: 2009 end-page: 459 ident: bb0150 article-title: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer publication-title: Cancer Immunol. Immunother. – volume: 390 start-page: 1949 year: 2017 end-page: 1961 ident: bb0385 article-title: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised publication-title: Lancet – volume: 27 start-page: 288 year: 2013 end-page: 294 ident: bb0395 article-title: Recurrent epithelial ovarian cancer: an update on treatment publication-title: Oncology (Williston Park) – volume: 15 start-page: 668 year: 2015 end-page: 679 ident: bb0080 article-title: Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer publication-title: Nat. Rev. Cancer – volume: 14 start-page: 5198 year: 2008 end-page: 5208 ident: bb0120 article-title: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome publication-title: Clin. Cancer Res. – reference: S. Zhang, B. Cui, H. Lai, G. Liu, E.M. Ghia, G.F. Widhopf, II, Z. Zhang, C.C. Wu, L. Chen, R. Wu, R. Schwab, D.A. Carson, T.J. Kipps, Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy, Proc. Natl. Acad. Sci. U. S. A., 111 (2014) 17266–17271. – volume: 31 start-page: 4718 year: 2012 end-page: 4724 ident: bb0235 article-title: Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair publication-title: Oncogene – volume: 24 start-page: 4699 year: 2006 end-page: 4707 ident: bb0035 article-title: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG publication-title: J. Clin. Oncol. – volume: 4 start-page: 9 year: 2002 end-page: 13 ident: bb0255 article-title: Distinct functions of BRCA1 and BRCA2 in double-strand break repair publication-title: Breast Cancer Res. – volume: 361 start-page: 2099 year: 2003 end-page: 2106 ident: bb0340 article-title: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial publication-title: Lancet – volume: 165 start-page: 1092 year: 2016 end-page: 1105 ident: bb0165 article-title: Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer publication-title: Cell – volume: 31 start-page: 16 year: 2015 end-page: 27 ident: bb0215 article-title: A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms publication-title: Semin. Cancer Biol. – volume: 125 start-page: 677 year: 2012 end-page: 682 ident: bb0260 article-title: BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer publication-title: Gynecol. Oncol. – volume: 23 start-page: 7621 year: 2017 end-page: 7632 ident: bb0125 article-title: A complex network of tumor microenvironment in human high-grade serous ovarian cancer publication-title: Clin. Cancer Res. – volume: 29 start-page: 3008 year: 2011 end-page: 3015 ident: bb0295 article-title: Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas publication-title: J. Clin. Oncol. – volume: 283 start-page: 361 year: 2011 end-page: 367 ident: bb0320 article-title: Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer publication-title: Arch. Gynecol. Obstet. – volume: 74 start-page: 135 year: 2018 end-page: 147 ident: bb0130 article-title: Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer publication-title: Hum. Pathol. – volume: 3 start-page: 251 year: 2013 ident: bb0245 article-title: Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment publication-title: Front. Oncol. – volume: 521 start-page: 489 year: 2015 end-page: 494 ident: bb0115 article-title: Whole-genome characterization of chemoresistant ovarian cancer publication-title: Nature – volume: 18 start-page: 869 year: 2012 end-page: 881 ident: bb0230 article-title: Stem cell pathways contribute to clinical chemoresistance in ovarian cancer publication-title: Clin. Cancer Res. – volume: 10 start-page: 325 year: 2011 end-page: 335 ident: bb0220 article-title: Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2 publication-title: Mol. Cancer Ther. – volume: 45 start-page: 712 year: 2016 end-page: 720 ident: bb0155 article-title: Minireview: Regulatory T Cells and Ovarian Cancer publication-title: Immunol. Investig. – volume: 4 year: 2009 ident: bb0145 article-title: Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors publication-title: PLoS One – volume: 177 start-page: 1053 year: 2010 end-page: 1064 ident: bb0095 article-title: Ovarian cancer development and metastasis publication-title: Am. J. Pathol. – volume: 7 year: 2016 ident: bb0110 article-title: Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1 publication-title: Nat. Commun. – volume: 122 start-page: 3297 year: 2016 end-page: 3306 ident: bb0030 article-title: Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer publication-title: Cancer – volume: 3 start-page: 256 year: 2013 ident: bb0075 article-title: Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research publication-title: Front. Oncol. – volume: 3 start-page: 137 year: 2017 end-page: 148 ident: bb0090 article-title: Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy failure publication-title: Trends Cancer – volume: 80 start-page: 11 year: 2018 end-page: 27 ident: bb0020 article-title: Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics publication-title: Hum. Pathol. – volume: 361 start-page: 2099 year: 2003 end-page: 2106 ident: bb0040 article-title: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial publication-title: Lancet – volume: 16 start-page: 1324 year: 2009 end-page: 1330 ident: bb0305 article-title: Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis publication-title: Ann. Surg. Oncol. – volume: 18 start-page: 75 year: 2017 end-page: 87 ident: bb0390 article-title: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial publication-title: The Lancet. Oncology – volume: 12 start-page: 31 year: 2012 end-page: 40 ident: bb0345 article-title: Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts publication-title: Expert. Rev. Anticancer. Ther. – volume: 37 start-page: 3778 year: 2018 end-page: 3789 ident: bb0195 article-title: Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway publication-title: Oncogene – volume: 81 start-page: 3 year: 2001 end-page: 9 ident: bb0325 article-title: Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer publication-title: Gynecol. Oncol. – volume: 108 start-page: 90 year: 2008 end-page: 94 ident: bb0330 article-title: Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200) publication-title: Gynecol. Oncol. – volume: 31 start-page: 1869 year: 2012 end-page: 1883 ident: bb0065 article-title: Molecular mechanisms of cisplatin resistance publication-title: Oncogene – volume: 132 start-page: 483 year: 2014 end-page: 489 ident: bb0205 article-title: Ovarian cancer stem cells: are they real and why are they important? publication-title: Gynecol. Oncol. – volume: Vol. 17 start-page: 1015 year: 2016 end-page: 1029 ident: bb0100 article-title: Omentum and Bone Marrow: How Adipocyte-Rich Organs Create Tumour Microenvironments Conducive for Metastatic Progression, Obesity Reviews : An Official Journal of the International Association for the Study of Obesity – volume: 4 start-page: 814 year: 2004 end-page: 819 ident: bb0275 article-title: Hallmarks of 'BRCAness' in sporadic cancers publication-title: Nat. Rev. Cancer – volume: 19 start-page: 361 year: 2009 end-page: 366 ident: bb0315 article-title: Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment publication-title: Int. J. Gynecol. Cancer – volume: 11 start-page: 8326 year: 2005 end-page: 8331 ident: bb0140 article-title: The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer publication-title: Clin. Cancer Res. – volume: 34 start-page: 433 year: 2010 ident: 10.1016/j.bbagen.2018.11.005_bb0175 article-title: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory publication-title: Am. J. Surg. Pathol. doi: 10.1097/PAS.0b013e3181cf3d79 – volume: 24 start-page: 4699 year: 2006 ident: 10.1016/j.bbagen.2018.11.005_bb0035 article-title: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2006.06.0913 – volume: 136 start-page: E359 year: 2015 ident: 10.1016/j.bbagen.2018.11.005_bb0010 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int. J. Cancer doi: 10.1002/ijc.29210 – volume: 18 start-page: 1193 year: 2000 ident: 10.1016/j.bbagen.2018.11.005_bb0360 article-title: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2000.18.6.1193 – volume: 521 start-page: 489 year: 2015 ident: 10.1016/j.bbagen.2018.11.005_bb0115 article-title: Whole-genome characterization of chemoresistant ovarian cancer publication-title: Nature doi: 10.1038/nature14410 – volume: 12 start-page: 31 year: 2012 ident: 10.1016/j.bbagen.2018.11.005_bb0345 article-title: Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts publication-title: Expert. Rev. Anticancer. Ther. doi: 10.1586/era.11.187 – volume: 19 start-page: 361 year: 2009 ident: 10.1016/j.bbagen.2018.11.005_bb0315 article-title: Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment publication-title: Int. J. Gynecol. Cancer doi: 10.1111/IGC.0b013e3181a1c7aa – volume: 15 start-page: 668 year: 2015 ident: 10.1016/j.bbagen.2018.11.005_bb0080 article-title: Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc4019 – volume: 165 start-page: 1092 year: 2016 ident: 10.1016/j.bbagen.2018.11.005_bb0165 article-title: Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer publication-title: Cell doi: 10.1016/j.cell.2016.04.009 – volume: 390 start-page: 1949 year: 2017 ident: 10.1016/j.bbagen.2018.11.005_bb0385 article-title: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised publication-title: Lancet doi: 10.1016/S0140-6736(17)32440-6 – volume: 132 start-page: 483 year: 2014 ident: 10.1016/j.bbagen.2018.11.005_bb0205 article-title: Ovarian cancer stem cells: are they real and why are they important? publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2013.12.001 – volume: 2 start-page: 275 year: 1990 ident: 10.1016/j.bbagen.2018.11.005_bb0290 article-title: Activation of programmed cell death by anticancer agents: cisplatin as a model system publication-title: Cancer Cells – volume: 14 start-page: 6624 year: 2013 ident: 10.1016/j.bbagen.2018.11.005_bb0225 article-title: Regulation of ovarian cancer stem cells or tumor-initiating cells publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms14046624 – volume: 107 start-page: 588 year: 2012 ident: 10.1016/j.bbagen.2018.11.005_bb0350 article-title: Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients publication-title: Br. J. Cancer doi: 10.1038/bjc.2012.307 – volume: 8 start-page: 963 year: 1997 ident: 10.1016/j.bbagen.2018.11.005_bb0060 article-title: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments] publication-title: Ann. Oncol. doi: 10.1023/A:1008240421028 – volume: 4 year: 2009 ident: 10.1016/j.bbagen.2018.11.005_bb0145 article-title: Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors publication-title: PLoS One doi: 10.1371/journal.pone.0006412 – volume: 3 start-page: 251 year: 2013 ident: 10.1016/j.bbagen.2018.11.005_bb0245 article-title: Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment publication-title: Front. Oncol. doi: 10.3389/fonc.2013.00251 – volume: 102 start-page: 18538 year: 2005 ident: 10.1016/j.bbagen.2018.11.005_bb0160 article-title: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0509182102 – volume: 97 start-page: 2187 year: 2003 ident: 10.1016/j.bbagen.2018.11.005_bb0265 article-title: Improved survival in women with BRCA-associated ovarian carcinoma publication-title: Cancer doi: 10.1002/cncr.11310 – volume: 104 start-page: 580 year: 2007 ident: 10.1016/j.bbagen.2018.11.005_bb0370 article-title: Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2006.09.006 – volume: 177 start-page: 1053 year: 2010 ident: 10.1016/j.bbagen.2018.11.005_bb0095 article-title: Ovarian cancer development and metastasis publication-title: Am. J. Pathol. doi: 10.2353/ajpath.2010.100105 – volume: 31 start-page: 16 year: 2015 ident: 10.1016/j.bbagen.2018.11.005_bb0215 article-title: A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2014.06.004 – volume: 10 start-page: 325 year: 2011 ident: 10.1016/j.bbagen.2018.11.005_bb0220 article-title: Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-10-0788 – volume: 17 start-page: 1498 year: 2011 ident: 10.1016/j.bbagen.2018.11.005_bb0105 article-title: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth publication-title: Nat. Med. doi: 10.1038/nm.2492 – volume: 18 start-page: 869 year: 2012 ident: 10.1016/j.bbagen.2018.11.005_bb0230 article-title: Stem cell pathways contribute to clinical chemoresistance in ovarian cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-2188 – volume: 3 start-page: 502 year: 2003 ident: 10.1016/j.bbagen.2018.11.005_bb0070 article-title: Ovarian cancer: strategies for overcoming resistance to chemotherapy publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1123 – volume: 122 start-page: 3297 year: 2016 ident: 10.1016/j.bbagen.2018.11.005_bb0030 article-title: Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer publication-title: Cancer doi: 10.1002/cncr.30196 – volume: 11 start-page: 8326 year: 2005 ident: 10.1016/j.bbagen.2018.11.005_bb0140 article-title: The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-05-1244 – volume: 37 start-page: 3778 year: 2018 ident: 10.1016/j.bbagen.2018.11.005_bb0195 article-title: Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway publication-title: Oncogene doi: 10.1038/s41388-018-0241-0 – volume: 16 start-page: 1324 year: 2009 ident: 10.1016/j.bbagen.2018.11.005_bb0305 article-title: Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-009-0357-0 – volume: 27 start-page: 288 year: 2013 ident: 10.1016/j.bbagen.2018.11.005_bb0395 article-title: Recurrent epithelial ovarian cancer: an update on treatment publication-title: Oncology (Williston Park) – volume: 146 start-page: 273 year: 2017 ident: 10.1016/j.bbagen.2018.11.005_bb0045 article-title: Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2017.05.023 – volume: 5 start-page: 301 year: 2014 ident: 10.1016/j.bbagen.2018.11.005_bb0210 article-title: Investigating molecular profiles of ovarian cancer: an update on cancer stem cells publication-title: J. Cancer doi: 10.7150/jca.8610 – ident: 10.1016/j.bbagen.2018.11.005_bb0240 – volume: 3 start-page: 256 year: 2013 ident: 10.1016/j.bbagen.2018.11.005_bb0075 article-title: Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research publication-title: Front. Oncol. doi: 10.3389/fonc.2013.00256 – volume: 14 start-page: 5198 year: 2008 ident: 10.1016/j.bbagen.2018.11.005_bb0120 article-title: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-08-0196 – volume: 139 start-page: 2391 year: 2016 ident: 10.1016/j.bbagen.2018.11.005_bb0005 article-title: Research fund international continuous update project, the use and interpretation of anthropometric measures in cancer epidemiology: a perspective from the world cancer research fund international continuous update project publication-title: Int. J. Cancer doi: 10.1002/ijc.30248 – volume: 283 start-page: 361 year: 2011 ident: 10.1016/j.bbagen.2018.11.005_bb0320 article-title: Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer publication-title: Arch. Gynecol. Obstet. doi: 10.1007/s00404-010-1462-9 – volume: 361 start-page: 2099 year: 2003 ident: 10.1016/j.bbagen.2018.11.005_bb0040 article-title: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial publication-title: Lancet doi: 10.1016/S0140-6736(03)13718-X – volume: 80 start-page: 11 year: 2018 ident: 10.1016/j.bbagen.2018.11.005_bb0020 article-title: Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2018.06.018 – volume: 11 start-page: 1 issue: Suppl. 6 year: 2015 ident: 10.1016/j.bbagen.2018.11.005_bb0025 article-title: Frontline treatment of epithelial ovarian cancer publication-title: Asia Pac. J. Clin. Oncol. doi: 10.1111/ajco.12449 – volume: 31 start-page: 1869 year: 2012 ident: 10.1016/j.bbagen.2018.11.005_bb0065 article-title: Molecular mechanisms of cisplatin resistance publication-title: Oncogene doi: 10.1038/onc.2011.384 – volume: 23 start-page: 7621 year: 2017 ident: 10.1016/j.bbagen.2018.11.005_bb0125 article-title: A complex network of tumor microenvironment in human high-grade serous ovarian cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-1159 – volume: 8 start-page: 1093 year: 2017 ident: 10.1016/j.bbagen.2018.11.005_bb0180 article-title: High grade serous ovarian carcinomas originate in the fallopian tube publication-title: Nat. Commun. doi: 10.1038/s41467-017-00962-1 – volume: 48 start-page: 2361 year: 2012 ident: 10.1016/j.bbagen.2018.11.005_bb0375 article-title: Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2012.04.001 – volume: 45 start-page: 712 year: 2016 ident: 10.1016/j.bbagen.2018.11.005_bb0155 article-title: Minireview: Regulatory T Cells and Ovarian Cancer publication-title: Immunol. Investig. doi: 10.1080/08820139.2016.1186689 – volume: 18 start-page: 75 year: 2017 ident: 10.1016/j.bbagen.2018.11.005_bb0390 article-title: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial publication-title: The Lancet. Oncology doi: 10.1016/S1470-2045(16)30559-9 – volume: 74 start-page: 135 year: 2018 ident: 10.1016/j.bbagen.2018.11.005_bb0130 article-title: Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2017.12.010 – volume: 26 start-page: 5530 year: 2008 ident: 10.1016/j.bbagen.2018.11.005_bb0270 article-title: "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2008.16.1703 – volume: 3 start-page: 137 year: 2017 ident: 10.1016/j.bbagen.2018.11.005_bb0090 article-title: Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy failure publication-title: Trends Cancer doi: 10.1016/j.trecan.2016.12.005 – volume: 6 start-page: 229 year: 2014 ident: 10.1016/j.bbagen.2018.11.005_bb0310 article-title: Treatment options in recurrent ovarian cancer: latest evidence and clinical potential publication-title: Ther. Adv. Med. Oncol. doi: 10.1177/1758834014544121 – volume: 28 start-page: 82 year: 2015 ident: 10.1016/j.bbagen.2018.11.005_bb0190 article-title: Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.05.009 – volume: 125 start-page: 1345 year: 2015 ident: 10.1016/j.bbagen.2018.11.005_bb0015 article-title: Trends in relative survival for ovarian cancer from 1975 to 2011 publication-title: Obstet. Gynecol. doi: 10.1097/AOG.0000000000000854 – volume: 58 start-page: 449 year: 2009 ident: 10.1016/j.bbagen.2018.11.005_bb0150 article-title: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-008-0583-5 – volume: 69 start-page: 1302 year: 2009 ident: 10.1016/j.bbagen.2018.11.005_bb0200 article-title: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-2741 – volume: 29 start-page: 3008 year: 2011 ident: 10.1016/j.bbagen.2018.11.005_bb0295 article-title: Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.34.2980 – volume: 4 start-page: 814 year: 2004 ident: 10.1016/j.bbagen.2018.11.005_bb0275 article-title: Hallmarks of 'BRCAness' in sporadic cancers publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1457 – volume: 31 start-page: 4718 year: 2012 ident: 10.1016/j.bbagen.2018.11.005_bb0235 article-title: Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair publication-title: Oncogene doi: 10.1038/onc.2011.610 – volume: 28 start-page: 3555 year: 2010 ident: 10.1016/j.bbagen.2018.11.005_bb0280 article-title: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.27.5719 – volume: 33 start-page: 3836 year: 2015 ident: 10.1016/j.bbagen.2018.11.005_bb0380 article-title: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA Trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.63.1408 – volume: 28 start-page: 3323 year: 2010 ident: 10.1016/j.bbagen.2018.11.005_bb0335 article-title: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.25.7519 – volume: 36 start-page: 207 year: 1990 ident: 10.1016/j.bbagen.2018.11.005_bb0055 article-title: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds publication-title: Gynecol. Oncol. doi: 10.1016/0090-8258(90)90174-J – volume: Vol. 17 start-page: 1015 year: 2016 ident: 10.1016/j.bbagen.2018.11.005_bb0100 – volume: 125 start-page: 677 year: 2012 ident: 10.1016/j.bbagen.2018.11.005_bb0260 article-title: BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2012.03.006 – volume: 134 start-page: 32 year: 2014 ident: 10.1016/j.bbagen.2018.11.005_bb0170 article-title: Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse publication-title: Int. J. Cancer doi: 10.1002/ijc.28335 – volume: 68 start-page: 2581 year: 2008 ident: 10.1016/j.bbagen.2018.11.005_bb0300 article-title: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-0088 – volume: 7 start-page: 925 year: 2006 ident: 10.1016/j.bbagen.2018.11.005_bb0085 article-title: Mechanisms of transcoelomic metastasis in ovarian cancer publication-title: Lancet Oncology doi: 10.1016/S1470-2045(06)70939-1 – volume: 361 start-page: 2099 year: 2003 ident: 10.1016/j.bbagen.2018.11.005_bb0340 article-title: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial publication-title: Lancet doi: 10.1016/S0140-6736(03)13718-X – volume: 9 start-page: 389 year: 1991 ident: 10.1016/j.bbagen.2018.11.005_bb0050 article-title: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1991.9.3.389 – volume: 10 start-page: 942 year: 2004 ident: 10.1016/j.bbagen.2018.11.005_bb0135 article-title: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival publication-title: Nat. Med. doi: 10.1038/nm1093 – volume: 19 start-page: 3312 year: 2001 ident: 10.1016/j.bbagen.2018.11.005_bb0365 article-title: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2001.19.14.3312 – volume: 15 start-page: 2183 year: 1997 ident: 10.1016/j.bbagen.2018.11.005_bb0355 article-title: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1997.15.6.2183 – volume: 5 year: 2010 ident: 10.1016/j.bbagen.2018.11.005_bb0185 article-title: Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma publication-title: PLoS One doi: 10.1371/journal.pone.0011198 – volume: 9 year: 2013 ident: 10.1016/j.bbagen.2018.11.005_bb0250 article-title: Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment publication-title: PLoS Comput. Biol. doi: 10.1371/journal.pcbi.1002975 – volume: 81 start-page: 3 year: 2001 ident: 10.1016/j.bbagen.2018.11.005_bb0325 article-title: Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer publication-title: Gynecol. Oncol. doi: 10.1006/gyno.2001.6151 – volume: 108 start-page: 90 year: 2008 ident: 10.1016/j.bbagen.2018.11.005_bb0330 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2007.08.075 – volume: 7 year: 2016 ident: 10.1016/j.bbagen.2018.11.005_bb0110 article-title: Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1 publication-title: Nat. Commun. doi: 10.1038/ncomms11150 – volume: 4 start-page: 9 year: 2002 ident: 10.1016/j.bbagen.2018.11.005_bb0255 article-title: Distinct functions of BRCA1 and BRCA2 in double-strand break repair publication-title: Breast Cancer Res. doi: 10.1186/bcr417 – volume: 740 start-page: 364 year: 2014 ident: 10.1016/j.bbagen.2018.11.005_bb0285 article-title: Cisplatin in cancer therapy: molecular mechanisms of action publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2014.07.025 |
| SSID | ssj0000595 |
| Score | 2.465401 |
| SecondaryResourceType | review_article |
| Snippet | Advanced epithelial ovarian cancer is one of the hardest human malignancies to treat. Standard treatment involves cytoreductive surgery and platinum-based... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 371 |
| SubjectTerms | cell viability DNA DNA repair drug therapy epithelium humans ovarian neoplasms patients platinum prediction relapse stem cells surgery women |
| Title | Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review |
| URI | https://dx.doi.org/10.1016/j.bbagen.2018.11.005 https://www.ncbi.nlm.nih.gov/pubmed/30423357 https://www.proquest.com/docview/2133436789 https://www.proquest.com/docview/2221062901 |
| Volume | 1863 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1872-8006 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000595 issn: 0304-4165 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect Complete Freedom Collection customDbUrl: eissn: 1872-8006 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000595 issn: 0304-4165 databaseCode: ACRLP dateStart: 19950118 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect Journals customDbUrl: eissn: 1872-8006 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000595 issn: 0304-4165 databaseCode: AIKHN dateStart: 19950118 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection 2013 customDbUrl: eissn: 1872-8006 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000595 issn: 0304-4165 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1872-8006 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000595 issn: 0304-4165 databaseCode: AKRWK dateStart: 19640113 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB5CQkkvJc3TSRq2kOva1j4k-RhMjNtSX9pAbsvuahUcYtn4Ucglvz0zXiklkNTQo8QsrHZm56GZ-QbgshQ6LzSGJSq3BSdAb-6CVTyxRSJ1jKGp2mKUDm_U91t9uwX9pheGyipr3R91-lpb12869Wl2ZuNx5xcl9dCd0CiUXakl6WFC_0KZbj_9LfNA90HHTILiRN20z61rvJzDS0soqEneJixPGmL3tnl6z_1cm6HBHnyq_Ud2Fbf4GbZCtQ8f4kTJx33Y7TcD3A6g_BmorXe8mCwYtYrNH6iliVlPxb-hYDMqg6tWE4YRN3mR-OlsXDECMGZ3c1sEhuI5XS3Y9A8G1LZinkjmjDPLCJGExbaXQ7gZXP_uD3k9VoF72dNLrnyGQWOSFlkaUN-JLE8IZMalJQ12E3gj0YnzQXRtoorglStFTwiLnPN5SEIij2C7mlbhBFg3LYUNPrOq61SZBWvRXXCZckVAeidbIJvTNL7GHKfRFw-mKS67N5EHhniA4YhBHrSAv6yaRcyNDfRZwyjzSnYMmoUNK782fDXIHMqV2CrgyRqBsbuSaMl7_6ARGC-nlIhuwXEUipf90l8iKXV2-t97O4OP-NSLFeLnsL2cr8IXdICW7mIt4Rewc_Xtx3D0DKv5AvM |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La-MwEB5KytK9LG32lT61sFdtYj1s51hCS_rKZVvoTUiyvKS0Tsij0H_fmcjOsrBtoVd7BLJmNJrPmvkG4GcpdF5ohCUqtwUnQm_uglU8sUUidcTQlG0xSoc36vxW327AoKmFobTK2vdHn77y1vWTbr2a3el43P1Nl3oYTmg0yp7UEv3wptLok1uweXx2MRz9dch61XyF5DkNaCroVmlezuG-JSLUJP9FdJ7Ux-7_J9RLEejqJDrdhk91CMmO4yx3YCNUbfgQm0o-tWFr0PRw-wzlVaDK3vH8Yc6oWmx2T1VNzHrK_w0Fm1ImXLV8YAi6KZDEr2fjihGHMfszs0VgaKGT5ZxNHhFT24p5EpkxziwjUhIWK1--wM3pyfVgyOvOCtzLvl5w5TPEjUlaZGlAlyeyPCGeGZeW1NtN4KbEOM4H0bOJKoJXrhR9ISwqz-chCYn8Cq1qUoXvwHppKWzwmVU9p8osWIsRg8uUKwLKO9kB2aym8TXtOHW_uDdNftmdiTowpANEJAZ10AG-HjWNtBtvyGeNosw_5mPwZHhj5I9GrwaVQ9cltgq4skYgfFcSD_P-KzICIXNKd9Ed-BaNYj1f-lEkpc523z23I9gaXl9dmsuz0cUefMQ3_Zgwvg-txWwZDjAeWrjD2t6fAXXUBZ4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanisms+underlying+acquired+platinum+resistance+in+high+grade+serous+ovarian+cancer+-+a+mini+review&rft.jtitle=Biochimica+et+biophysica+acta.+General+subjects&rft.au=Binju%2C+Mudra&rft.au=Padilla%2C+Monica+Amaya&rft.au=Singomat%2C+Terence&rft.au=Kaur%2C+Pritinder&rft.date=2019-02-01&rft.issn=0304-4165&rft.volume=1863&rft.issue=2+p.371-378&rft.spage=371&rft.epage=378&rft_id=info:doi/10.1016%2Fj.bbagen.2018.11.005&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-4165&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-4165&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-4165&client=summon |